secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001193125-25-311221
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.03, 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics borrows $50M under amended Hercules loan; up to $125M additional available
--------------------------------------------------------------------------------

- Borrowed $50M second tranche under amended Loan and Security Agreement with Hercules Capital.
- Two additional tranches of up to $75M available upon achieving clinical, regulatory, and commercial milestones.
- Final tranche of up to $50M subject to Lenders' investment committee approval.
- Maturity July 1, 2030; interest at WSJ Prime + 2.45% (floor 7.50%); interest-only until July 2028.
- Collateral includes first-priority security interest in substantially all assets, including IP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525311221/0001193125-25-311221-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525311221/d16982d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-311221

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer